Literature DB >> 21385915

Assessment of ablative margin by MRI with ferucarbotran in radiofrequency ablation for liver cancer: comparison with enhanced CT.

S Tokunaga1, M Koda, T Matono, T Sugihara, T Nagahara, M Ueki, Y Murawaki, S Kakite, E Yamashita.   

Abstract

OBJECTIVES: Our aim was to determine whether ablated liver parenchyma surrounding a tumour can be assessed by MRI with ferucarbotran administered prior to radiofrequency ablation (RFA) compared with enhanced CT.
METHODS: 55 hepatocellular carcinomas (HCCs) in 42 patients and 5 metastatic liver cancers in 3 patients were treated by RFA after ferucarbotran administration. We then performed T(2)* weighted MRI after 1 week and enhanced CT after 1 month. T(2)* weighted MRI demonstrated the ablated parenchyma as a low-intensity rim around the high intensity of the ablated tumour in these cases. The assessment was allocated to one of three grades: margin (+), high-intensity area with continuous low-intensity rim; margin zero, high-intensity area with discontinuous low-intensity rim; and margin (-), high-intensity area extending beyond the low-intensity rim.
RESULTS: Margin (+), margin zero and margin (-) were found in 17, 35 and 5 nodules, respectively. All 17 nodules with margin (+) and 13 of those with margin zero were assessed as having sufficient ablative margins on CT. The remaining 22 nodules with margin zero had insufficient margins on CT. The overall agreement between MRI and CT for the diagnosis of the ablative margin was moderate (κ = 0.507, p < 0.001). No local recurrence was found in 15 HCC nodules with margin (+), whereas local recurrence was found in 4 (11.8%) out of 34 HCC nodules with margin zero.
CONCLUSION: Administration of ferucarbotran before RFA enables the ablative margin to be visualised as a low-intensity rim, and also enables the evaluation of the ablative margin to be made earlier and more easily than with enhanced CT.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21385915      PMCID: PMC3474088          DOI: 10.1259/bjr/64518148

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  24 in total

1.  Relaxation effects of clustered particles.

Authors:  A Tanimoto; K Oshio; M Suematsu; D Pouliquen; D D Stark
Journal:  J Magn Reson Imaging       Date:  2001-07       Impact factor: 4.813

Review 2.  Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors.

Authors:  Stefaan Mulier; Yicheng Ni; Jacques Jamart; Theo Ruers; Guy Marchal; Luc Michel
Journal:  Ann Surg       Date:  2005-08       Impact factor: 12.969

3.  Assessment of the ablated area after radiofrequency ablation by contrast-enhanced sonography; comparison with virtual sonography with magnetic navigation.

Authors:  Masahiko Koda; Mari Mandai; Tomomitu Matono; Takaaki Sugihara; Takakazu Nagahara; Masaru Ueki; Kenji Ohyama; Keiko Hosho; Yoshikazu Murawaki
Journal:  Clin Imaging       Date:  2010 Jan-Feb       Impact factor: 1.605

4.  Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features.

Authors:  Takuji Okusaka; Shuichi Okada; Hideki Ueno; Masafumi Ikeda; Kazuaki Shimada; Junji Yamamoto; Tomoo Kosuge; Susumu Yamasaki; Noriyoshi Fukushima; Michiie Sakamoto
Journal:  Cancer       Date:  2002-11-01       Impact factor: 6.860

5.  Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection.

Authors:  T Livraghi; S N Goldberg; S Lazzaroni; F Meloni; L Solbiati; G S Gazelle
Journal:  Radiology       Date:  1999-03       Impact factor: 11.105

6.  Superparamagnetic iron oxide-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading.

Authors:  Y Imai; T Murakami; S Yoshida; M Nishikawa; M Ohsawa; K Tokunaga; M Murata; K Shibata; S Zushi; M Kurokawa; T Yonezawa; S Kawata; M Takamura; H Nagano; M Sakon; M Monden; K Wakasa; H Nakamura
Journal:  Hepatology       Date:  2000-08       Impact factor: 17.425

7.  Pathomorphological study on location and distribution of Kupffer cells in hepatocellular carcinoma.

Authors:  Kai Liu; Xu He; Xue-Zhong Lei; Lian-San Zhao; Hong Tang; Li Liu; Bing-Jun Lei
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

8.  Radiofrequency ablation of hepatocellular carcinoma: therapeutic response using contrast-enhanced coded phase-inversion harmonic sonography.

Authors:  Yan Ling Wen; Masatoshi Kudo; Rong Qin Zheng; Yasunori Minami; Hobyung Chung; Yoichiro Suetomi; Hirokazu Onda; Masayuki Kitano; Toshihiko Kawasaki; Kiyoshi Maekawa
Journal:  AJR Am J Roentgenol       Date:  2003-07       Impact factor: 3.959

9.  Contrast-enhanced MR imaging of liver and spleen: first experience in humans with a new superparamagnetic iron oxide.

Authors:  B Hamm; T Staks; M Taupitz; R Maibauer; A Speidel; A Huppertz; T Frenzel; R Lawaczeck; K J Wolf; L Lange
Journal:  J Magn Reson Imaging       Date:  1994 Sep-Oct       Impact factor: 4.813

10.  Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver.

Authors:  D D Stark; R Weissleder; G Elizondo; P F Hahn; S Saini; L E Todd; J Wittenberg; J T Ferrucci
Journal:  Radiology       Date:  1988-08       Impact factor: 11.105

View more
  8 in total

1.  A measure to assess the ablative margin using 3D-CT image fusion after radiofrequency ablation of hepatocellular carcinoma.

Authors:  Hui Tang; Yunqiang Tang; Jian Hong; Tiejun Chen; Cong Mai; Peng Jiang
Journal:  HPB (Oxford)       Date:  2014-10-24       Impact factor: 3.647

2.  Insufficient ablative margin determined by early computed tomography may predict the recurrence of hepatocellular carcinoma after radiofrequency ablation.

Authors:  Wei Teng; Ka-Wai Liu; Chen-Chun Lin; Wen-Juei Jeng; Wei-Ting Chen; I-Shyan Sheen; Chun-Yen Lin; Shi-Ming Lin
Journal:  Liver Cancer       Date:  2015-03       Impact factor: 11.740

3.  Radiofrequency ablation for hepatocellular carcinoma: the relationship between a new grading system for the ablative margin and clinical outcomes.

Authors:  Hiroki Nishikawa; Yukio Osaki; Eriko Iguchi; Haruhiko Takeda; Fumihiro Matsuda; Jun Nakajima; Azusa Sakamoto; Keiichi Hatamaru; Sumio Saito; Akihiro Nasu; Ryuichi Kita; Toru Kimura
Journal:  J Gastroenterol       Date:  2012-10-12       Impact factor: 7.527

4.  Ablative margin states by magnetic resonance imaging with ferucarbotran in radiofrequency ablation for hepatocellular carcinoma can predict local tumor progression.

Authors:  Masahiko Koda; Shiho Tokunaga; Kennichi Miyoshi; Manabu Kishina; Yuki Fujise; Jun Kato; Tomomitsu Matono; Yoshikazu Murawaki; Suguru Kakite; Eijiro Yamashita
Journal:  J Gastroenterol       Date:  2013-01-22       Impact factor: 7.527

Review 5.  A perspective on a rapid and radiation-free tracer imaging modality, magnetic particle imaging, with promise for clinical translation.

Authors:  Prashant Chandrasekharan; Zhi Wei Tay; Xinyi Yedda Zhou; Elaine Yu; Ryan Orendorff; Daniel Hensley; Quincy Huynh; K L Barry Fung; Caylin Colson VanHook; Patrick Goodwill; Bo Zheng; Steven Conolly
Journal:  Br J Radiol       Date:  2018-06-21       Impact factor: 3.039

6.  Evaluation of the ablation margin of hepatocellular carcinoma using CEUS-CT/MR image fusion in a phantom model and in patients.

Authors:  Kai Li; Zhongzhen Su; Erjiao Xu; Qiannan Huang; Qingjing Zeng; Rongqin Zheng
Journal:  BMC Cancer       Date:  2017-01-19       Impact factor: 4.430

7.  Improvement of ablative margins by the intraoperative use of CEUS-CT/MR image fusion in hepatocellular carcinoma.

Authors:  Kai Li; Zhong-Zhen Su; Er-Jiao Xu; Jin-Xiu Ju; Xiao-Chun Meng; Rong-Qin Zheng
Journal:  BMC Cancer       Date:  2016-04-18       Impact factor: 4.430

8.  Active contour configuration model for estimating the posterior ablative margin in image fusion of real-time ultrasound and 3D ultrasound or magnetic resonance images for radiofrequency ablation: an experimental study.

Authors:  Junkyo Lee; Min Woo Lee; Dongil Choi; Dong Ik Cha; Sunyoung Lee; Tae Wook Kang; Jehoon Yang; Jaemoon Jo; Won-Chul Bang; Jongsik Kim; Dongkuk Shin
Journal:  Ultrasonography       Date:  2017-12-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.